If you have been reading about IGF-1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Itching Nausea Sedation Respiratory depression - can be potentially life-threatening However, since viminol is supplied as a racemic mixture of agonist and antagonist isomers, the abuse potential and respiratory depression tends to be less than that of μ-opioid full agonist drugs. Drug dependence may occur.
=== Hari Dhar === Hari Dhar (Nabhaan Rizwan) is a new grad assigned to Pierpoint's IBD desk alongside Gus. Having come from a family of Indian immigrants and graduated from a state school, Hari feels out of place among Pierpoint's new grads, and overcompensates by working through the night at the office, sleeping in the bathrooms, skipping nights out with his colleagues, and abusing energy drinks and stimulant pills to stay awake. Within days, Hari dies of a heart attack in Pierpoint's bathroom stalls. Pierpoint does brief damage control before going back to business as usual. However, Hari's death causes many Pierpoint employees to reflect on the cutthroat culture of investment banking, and plays a role in Gus' eventual decision to leave the firm.
=== Cancer research === For hundreds of years, S. mutilans was used in traditional Chinese medicine for cancer treatment and other curative effects. Arthropod medicines were found to have a high level of antitumour effect in modern studies, and centipede is one of the major constituents of such medication. Extraction from these centipedes was found to be effective in controlling the proliferation of HepG2 cells (liver cancer). The mechanism by which the centipede extract alleviates liver cancer is related to the regulation of PI3/AKT, STA3, and MAPK signalling pathways. Water extracts from the dried whole body of this species were reported to have antitumour properties, and would lead to enhanced immune responses. SPPC is a polysaccharide-protein complex that can be extracted from the centipede by pouring hot water over the powdered, dried body of the organism. In mice clinical trials, SPPC was found to effectively suppress the growth of S180 cancer cell in mice by promoting both specific and nonspecific immune responses. H22-bearing mice were found to have extended survival time with the administration of SPPC.
Sources: en.wikipedia.org
In March 2013, the City of Pittsburgh filed a lawsuit in Federal court challenging the tax exempt status of UPMC as a public charity, in an effort to make UPMC to pay back taxes. The city alleged that UPMC has abused its status to avoid paying property taxes. The city dropped its lawsuit in 2014. In February 2019, the Pennsylvania Attorney General submitted legal actions against UPMC to enforce requirements for open health care access based on the non-profit status of UPMC. These actions stem from a long-standing dispute between Highmark Health and UPMC, the largest two health-care providers in Western PA. In 2011, Highmark entered a partnership with West Penn Hospital System (now Allegheny Health Network). Because of this competitive threat, UPMC declared they would not accept Highmark Blue Cross Blue Shield Insurance. In order to protect public access to health care while agreements between the two systems unwound, both UPMC and Highmark Health accepted a state-brokered consent decree. With the consent decree expiring in 2019, the Pennsylvania Attorney General attempted to negotiate continued access to care with both companies. Highmark indicated that it would accept the terms while UPMC did not. It is the failure to accept the proposal that the PA Attorney General cited as leading to the legal actions of February 2019.
Benzyl chloroformate, also known as benzyl chlorocarbonate or Z-chloride, is the benzyl ester of chloroformic acid. It can be also described as the chloride of the benzyloxycarbonyl (Cbz or Z) group. In its pure form it is a water-sensitive oily colorless liquid, although impure samples usually appear yellow. It possesses a characteristic pungent odor and degrades in contact with water. The compound was first prepared by Leonidas Zervas in the early 1930s who used it for the introduction of the benzyloxycarbonyl protecting group, which became the basis of the Bergmann-Zervas carboxybenzyl method of peptide synthesis he developed with Max Bergmann. This was the first successful method of controlled peptide chemical synthesis and for twenty years it was the dominant procedure used worldwide until the 1950s. To this day, benzyl chloroformate is often used for amine group protection.
Glycine MS Spectrum Glycine Glycine cleavage system Glycine Therapy – A New Direction for Schizophrenia Treatment? ChemSub Online (Glycine). NASA scientists have discovered glycine, a fundamental building block of life, in samples of comet Wild 2 returned by NASA's Stardust spacecraft.
Sources: en.wikipedia.org
== History == As Eucalyptus Health shifted its telehealth services into obesity and metabolic health in the early 2020s, Juniper became one of its primary brands. The change aligned with the growing global demand for GLP-1 receptor agonist medications. In 2023, the Australian operations of weight-loss company Jenny Craig went into voluntary administration. Eucalyptus Health acquired the assets, including their online infrastructure, to broaden their services across brands, including Juniper.
1,6-Dichloro-1,6-dideoxyfructose (dichlorodideoxyfructose) is chlorinated derivative of the sugar fructose. It is one of the two components believed to comprise the disaccharide sucralose, a commercial sugar substitute.
==== Enteral/gastrointestinal route ==== Through the gastrointestinal tract is sometimes termed enteral or enteric administration (literally meaning 'through the intestines'). Enteral/enteric administration usually includes oral (through the mouth) and rectal (into the rectum) administration, in the sense that these are taken up by the intestines. However, uptake of drugs administered orally may also occur already in the stomach, and as such gastrointestinal (along the gastrointestinal tract) may be a more fitting term for this route of administration. Furthermore, some application locations often classified as enteral, such as sublingual (under the tongue) and sublabial or buccal (between the cheek and gums/gingiva), are taken up in the proximal part of the gastrointestinal tract without reaching the intestines. Strictly enteral administration (directly into the intestines) can be used for systemic administration, as well as local (sometimes termed topical), such as in a contrast enema, whereby contrast media are infused into the intestines for imaging. However, for the purposes of classification based on location of effects, the term enteral is reserved for substances with systemic effects.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.